Cavinton, 5 mg/ml 10 ml 10 pcs

Cavinton is a drug that improves cerebral blood flow, cerebral metabolism and rheological properties of blood.
It has cerebroprotective effect. It reduces severity of damaging cytotoxic reactions caused by stimulating amino acids; inhibits functional activity of both cellular transmembrane sodium and calcium channels and NMDA and AMPA receptors. Potentiates neuroprotective effect of adenosine.

Stimulates brain metabolism, increases absorption and assimilation of glucose and oxygen by brain. Stimulates the transport of glucose through the GEB, shifts glucose metabolism in an energetically more favorable aerobic direction. Selectively inhibits Ca²⁺-calmodulin-dependent cGMP-phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissues, as well as ATP concentration and ATP/AMP ratio. It stimulates cerebral metabolism of noradrenaline and serotonin, stimulates the ascending noradrenergic system and has an antioxidant effect.

The drug selectively increases cerebral blood flow: increases cerebral fraction of minute volume; decreases resistance of cerebral vessels without affecting parameters of total blood circulation (BP, minute volume, HR, RPS).

It does not cause the phenomenon of “stealing”; on the contrary, its use primarily increases the blood supply to the ischemic, but still viable area with low perfusion – the phenomenon of “reverse stealing”.

It improves the tolerance of hypoxia by brain cells by promoting the transport of oxygen to the tissues due to a decrease in the affinity of red blood cells for it.

The drug improves microcirculation in the brain, inhibits platelet aggregation, reduces abnormally high blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Indications

In neurology – acute and chronic cerebral circulatory failure (transient ischemia, progressive stroke, post-stroke conditions, vascular dementia, cerebral atherosclerosis, post-traumatic and hypertensive encephalopathy, vertebrobasilar insufficiency); mental and neurological disorders in patients with cerebrovascular insufficiency (including memory impairment, dizziness, headache, aphasia, apraxia, movement disorders).

In ophthalmology – vascular diseases of the eyes (atherosclerosis, vasospasm of the choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).

In ENT practice – hearing loss (vascular, toxic or age-related), Meniere’s disease, cochleovestibular neuritis, tinnitus, dizziness (of labyrinthine origin); vasovegetative manifestations of menopausal syndrome.

Pharmacological effect

Cavinton is a drug that improves cerebral circulation, cerebral metabolism and rheological properties of blood.
Has a cerebroprotective effect. Reduces the severity of damaging cytotoxic reactions caused by stimulating amino acids; inhibits the functional activity of both cellular transmembrane sodium and calcium channels, and NMDA and AMPA receptors. Potentiates the neuroprotective effect of adenosine.

Stimulates brain metabolism, enhances the absorption and assimilation of glucose and oxygen by the brain. Stimulates glucose transport across the BBB, shifts glucose metabolism to an energetically more favorable aerobic direction. Selectively inhibits Ca2+-calmodulin-dependent cGMP phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissue, as well as the concentration of ATP and the ATP/AMP ratio. Stimulates the cerebral metabolism of norepinephrine and serotonin, stimulates the ascending noradrenergic system, and has an antioxidant effect.

The drug selectively enhances cerebral blood flow: increases the cerebral fraction of minute volume; reduces cerebral vascular resistance without affecting the parameters of general circulation (blood pressure, minute volume, heart rate, peripheral resistance).

Does not cause the phenomenon of “robbing”; on the contrary, its use primarily increases the blood supply to the ischemic but still viable area with low perfusion – the phenomenon of “reverse steal”.

Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it.

The drug improves brain microcirculation, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Special instructions

Cavinton does not have hepato- and nephrotoxic effects, therefore, when prescribing the drug to patients with liver and kidney diseases, no dosage adjustment is required.
Use in pediatrics
It is not recommended to prescribe the drug to children under 18 years of age due to the lack of experience in using Cavinton in this category of patients.

Active ingredient

Vinpocetine

Composition

1 ml contains vinpocetine 5 mg. 1 amp. – 50 mg.

Excipients:

ascorbic acid,

sodium disulfite,

tartaric acid,

benzyl alcohol,

sorbitol,

water d/i.

Pregnancy

The drug is contraindicated during pregnancy and lactation.

Contraindications

Acute phase of hemorrhagic stroke;
Severe form of ischemic heart disease;
Severe arrhythmias;
Age under 18 years (due to insufficient data);
Known hypersensitivity to vinpocetine.

Side Effects

From the cardiovascular system: it is possible to increase the manifestations of existing arrhythmia.

From the digestive system: nausea, heartburn, dry mouth.

From the central nervous system: headache, dizziness, sleep disturbance, weakness.

Allergic reactions: skin rash, urticaria.

Skin reactions: hyperemia of the skin.

Overdose

Currently, data on overdose of Cavinton are limited.

Treatment: symptomatic therapy.

Storage conditions

In a place protected from light, at a temperature of 15–30 °C

Shelf life

5 years

Manufacturer

Gedeon Richter, Hungary